FDA approves Epclusa for treatment of chronic hepatitis C virus infection
The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus both with and without cirrhosis. For patients with moderate to severe cirrhosis, Epclusa is approved for use in combination with the drug ribavirin. Epclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063